Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity

Title:Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity

Volume: 21 Issue: 16

Author(s): Milica M. Borovcanin*, Gordana D. Radosavljevic, Jelena Pantic, Jelena Milovanovic, Natasa R. Mijailovic, Aleksandar N. Arsenijevic and Nebojsa N. Arsenijevic

Affiliation:

• Department of Psychiatry, Faculty of Medical Sciences, University of Kragujevac, Kragujevac,Serbia

Keywords: Cognition, Comorbidity, Galectin-3, Neuroinflammation, Neurodegeneration, Psychosis, Schizophrenia.

Abstract: The role of the Galectin-3 (Gal-3) has already been explored in various somatic diseases, considering its engagement in infection, acute and chronic inflammation, and autoimmunity. Additionally, it has been recognized that Gal-3 is included in neuroinflammation and neurodegeneration, so we presented the possibility for its involvement in neuroprogression in schizophrenia. Gal-3 possibly participates in the early life programming of schizophrenia, also in the specific response to viral infections as a “second hit” later in life, and as a part of a unique systemic somatic dysfunction leading to the specific mental changes. In this review, we would like to put all these previous observations of Gal-3 properties in the context of schizophrenia onset, clinical symptoms presentation, frequent somatic comorbid states, and future options for Gal-3 centered treatment in schizophrenia.

Cite this article as:

Borovcanin M. Milica *, Radosavljevic D. Gordana , Pantic Jelena, Milovanovic Jelena , Mijailovic R. Natasa , Arsenijevic N. Aleksandar and Arsenijevic N. Nebojsa , Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity, Current Topics in Medicinal Chemistry 2021; 21 (16) . https://dx.doi.org/10.2174/1568026621666210611162420